SecBot SecBot

PHAT

Phathom Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001783183 Biotech & Drug Discovery
$5.88 −0.18 (−2.97%)
Nov 16 4:00 PM ET · prev $6.06
Market cap
$506.4M
Small cap
Consensus
Buy
88% Buy or better · 17 analysts
Median target
$21.50
+266% · range $7.50–29.00
1 year
−59.2%
from $14.41 · Nov 17
30 days
−16.1%
from $7.01
52-week range
$5.08–18.08
−67% from high · low Nov 5
Avg volume 20D
1.87M
Oct 23 spike 4.86M
Short interest
9.20M
≈11.3% of shares · −5.9%
Days to cover
4.8
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read MIXED 8 reports · 90 days
Balance 2 bearish · 2 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 8/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q3 2026: 23 added (0 new), 13 trimmed or exited.

  • AnalystsBULLISH

    15 of 17 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −5.9% to 9.20M shares. 4.8 days to cover, ≈11.3% of shares.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
WASATCH ADVISORS LPDOUBLED2,942,432$21.5M
STATE STREET CORPADD1,997,876$14.6M
UBS Group AGADD376,377$2.7M
BNP PARIBAS FINANCIAL MARKETSDOUBLED196,286$1.4M
Squarepoint Ops LLCDOUBLED140,601$1.0M
MORGAN STANLEYTRIM107,457$784.4K
BARCLAYS PLCDOUBLED107,091$781.8K
CITIGROUP INCADD86,279$629.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 88% rate it Buy or better
Strong Buy6Buy9Hold2Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +266%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 9, 2026Leerink Partners
INITIATE
INITIATEMarket Perform
Aug 17, 2026Barclays
MAINTAIN
MAINTAINOverweight
Jul 31, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Jul 31, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 30, 2026Needham
MAINTAIN
MAINTAINBuy
Jun 17, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 6, 2026
Narula Sanjeev
Chief Financial & Bus. Officer
Oct 6, 2026
TAX W/H$91.4K
Sep 3, 2026
Breedlove Robert Charles
Principal Accounting Officer
Sep 3, 2026
TAX W/H$4.2K
Jul 14, 2026
Breedlove Robert Charles
Principal Accounting Officer
Jul 14, 2026
TAX W/H$17.2K
May 22, 2026
Parikh Asit
Director
May 22, 2026
GIFT28,000 sh
May 20, 2026
Parikh Asit
Director
May 20, 2026
EXERCISE$86.6K
May 20, 2026
Parikh Asit
Director
May 20, 2026
TO ISSUER17,500 sh
May 19, 2026
Parikh Asit
Director
May 19, 2026
AWARD24,122 sh
May 19, 2026
KARBE FRANK
Director
May 19, 2026
AWARD24,122 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q$0.02-$0.03–$0.07-73.9%$94.0M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

8 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
9,204,035
shares short
-5.9%
vs prior settlement
4.8
days to cover
≈11.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 SEC
Invesco Ltd. filed an amendment to its Schedule 13G for Phathom Pharmaceuticals, reporting beneficial ownership of…
SC 13G/A · Impact 2/10
Nov 4, 2026 Other
Phathom Pharmaceuticals to Participate in November Investor Conferences
FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),
Nov 2, 2026 SEC
Frazier Life Sciences filed Amendment No. 12 to its Schedule 13D for Phathom Pharmaceuticals, reporting aggregate…
SC 13D/A · Impact 3/10
Oct 29, 2026 SEC
Phathom Pharmaceuticals reported Q3 2026 net revenue of $84.7M, up 71% YoY and 14% sequentially, and generated…
8-K · Impact 6/10
Oct 6, 2026 Insider
Narula Sanjeev surrendered for taxes 13,485 shares
Chief Financial & Bus. Officer @ $6.78 ($91.4K)
Sep 30, 2026 Inst.
WASATCH ADVISORS LP · DOUBLED
2,942,432 shares ($21.5M)
Sep 30, 2026 Inst.
STATE STREET CORP · ADD
1,997,876 shares ($14.6M)
Sep 3, 2026 Insider
Breedlove Robert Charles surrendered for taxes 460 shares
Principal Accounting Officer @ $9.05 ($4.2K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 4, 2026
Press release
Phathom Pharmaceuticals to Participate in November Investor Conferences
FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on…
Nov 3, 2026
Press release
Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
A Media Snippet accompanying this announcement is available by clicking on this link.
Oct 29, 2026
Earnings
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
FLORHAM PARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on…
Oct 29, 2026
Earnings result
PHAT Q3 2026 Earnings: EPS $0.04 (+128.3% vs est)
Oct 26, 2026
Press release
Phathom Pharmaceuticals Provides Update on FDA Litigation
FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on…

SecBot reports

14 filings · 2 press releases · 3 bullish · 3 bearish · 2 mixed · 6 neutral
All PHAT filing & press-release reports (16)